Genlight Medical has completed consecutive C and D financing rounds, raising several hundred million yuan in total. The C round was led by Qiming Venture Partners, while the D round was backed by Saizhi Bole, Kuanqiao Hengsong, Ningbo state capital and other investors.
The company plans to use the funds to advance registration and commercialization of its Epilcure implantable neurostimulation system for drug-resistant focal epilepsy, as well as clinical translation of its Vivastep spinal interface and regulatory filings and clinical collaborations overseas. [TechNode reporting]